Watson launches generic of ViroPharma's antibiotic

Tue Apr 10, 2012 6:15pm IST

Related Topics

Priyanka Gandhi Vadra, daughter of Congress party chief Sonia Gandhi, adjusts her flower garlands as she campaigns for her mother during an election meeting at Rae Bareli in Uttar Pradesh April 22, 2014. REUTERS/Pawan Kumar

Election 2014

More than 814 million people — a number larger than the population of Europe — are eligible to vote in the world’s biggest democratic exercise.  Full Coverage 

(Reuters) - Generic drugmaker Watson Pharmaceuticals Inc said U.S. health regulators approved its copycat version of ViroPharma Inc's antibiotic Vancocin.

Separately, ViroPharma said the U.S. Food and Drug Administration declined its citizen petition, which was filed to prevent Watson from launching the generic version.

Shares of ViroPharma were trading down 18 percent at $23.40 in premarket.

Watson said it has started shipping the drug, which recorded sales of $332 million for the 12 months ended February 29, 2012.

ViroPharma shares closed at $28.61 on Monday on the Nasdaq.

(Reporting by Anand Basu in Bangalore; Editing by Sriraj Kalluvila)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Fighting TB

REUTERS SHOWCASE

Only For Adults

Only For Adults

FDA moves to ban sales of e-cigarettes to minors.  Full Article 

For Diabetics

For Diabetics

Weight loss plan better than usual diet for diabetes patients.  Full Article 

Depends On DNA

Depends On DNA

Aspirin's benefit in preventing colon cancer depends on DNA.  Full Article 

STD Risk

STD Risk

Could shared sex toys transmit HPV?  Full Article 

Marijuana Use

Marijuana Use

France sees small increase in pot-related heart problems.  Full Article 

Internet Effect

Internet Effect

Retirees who use the Internet less likely to be depressed: study.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage